BNET Industries
Market Cap:$191.7M
Last Fiscal Year Sales:$47.1M
- Public
- US
Dow Jones Description
We are a genetics company committed to providing genetic analysis products, services and diagnostic applications. Our products and services are designed to translate the results of genomic research into solutions for biomedical research, translational research, molecular medicine applications and research conducted in the agro (agricultural and livestock) industry. Our development efforts in various diagnostic applications include areas of noninvasive diagnostics in prenatal, oncology and infectious diseases and other disorders. Our proprietary MassARRAY system, comprised of hardware, software applications, consumable chips and reagents, is a high performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. Our MassARRAY research and development efforts are committed to producing new and improved components and applications that deliver greater system versatility and reduce the cost per data point generated. MassARRAY technology is widely accepted as a leading high-performance DNA analysis platform for the fine mapping genotyping and quantitative gene expression markets and is gaining traction in new developing markets, such as epigenomics and pathogen typing. Our customers include some of the worldwide premier clinical research laboratories, biotechnology companies and academic institutions, as well as various government agencies. ...
Number of Employees 248
Contact Information
3595 John Hopkins Ct
San Diego, California 92121-1331
(858) 202-9000
Peer Companies
NAICS Code : 541710
News & Analysis
Filter by
sequenom inc. - All News and Analysis
Sequenom, Inc. Q3 2009 Earnings Call Transcript
Seeking Alpha
- 2009-11-09
Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Ram Selvaraju of Hapoalim Securities. Ram Selvaraju - Hapoalim Securities A couple of financial related items, first of all, can you please give me the number of shares outstanding as of the end of the quarter, please?...
Sequenom: Heads Roll, Investors Struggle to Find the Bottom
Seeking Alpha
- 2009-09-30
Brendan Wagner submits: After an independent board investigation, Sequenom SQNM has fired arguably the three most important people in a biotech outfit - its CEO, CFO, and head of Research & Development. At the bottom of this piece is a look at attempts to peg a fair value for these...
Something's Rotten in the State of Sequenom (But Who Really Cares?)
Seeking Alpha
- 2009-09-29
Trader Mark submits: The drama never ceases at Sequenom SQNM; there appears to be a purging of upper management after investigations into what went wrong with the company's Down Syndrome's test. [Apr 29, 2009: Sequenom Bombshell] After *that* revelation (and stock plunge from $15 to $3s) speculators have returned to...
Sequenom Reaches Important Milestone
Seeking Alpha
- 2009-09-23
Hello future. It did not take us long to welcome the arrival of what many have expected from Sequenom SQNM and many have doubted. The expected has, indeed, begun to show, and the doubt that should disappear will stay as long as the skeptics of Wall street are ideologists...
Spectrum Pharmaceuticals, Sequenom Shares Rise on Heavy Volume
Seeking Alpha
- 2009-09-01
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) jumped on twice the average volume Monday. Shares for the biopharmaceutical company, which focuses on pioneering novel cancer therapies with a focus primarily in the areas of hematology-oncology and urology, are under a heavy accumulation which is related to Spectrum’s dealings with the FDA,...
Who Sold Sequenom Last Week and Why?
Seeking Alpha
- 2009-08-10
Sequenom’s SQNM recent stock decline looked as if a program was set for selling SQNM as soon as the financial results were announced. The point is that the firm’s financial results had nothing to do with SQNM's price move, neither during the rally that took the stock up from a...
SEQUENOM, Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-08-06
Question-and-Answer SessionOperator Operator Instructions. Harry Stylli While we wait for our question queue to be compiled or complied, I would like to take a moment to welcome a couple of new additions to our leadership team. Clinical operations are clearly an important focus for the company. I'm delighted...
SEQUENOM, Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-08-06
SEQUENOM, Inc. SQNM Q2 2009 Earnings Call August 6, 2009 4:30 am ET
Sequenom and the Small Cap Biotech Bipolar Experience
Seeking Alpha
- 2009-06-02
Trader Mark submits: Still keeping my eye on the Sequenom SQNM, but the whole idea with this name was to avoid the small cap "biotech" bipolar experience either a huge win or a huge loss. Unfortunately, this is what this has now turned to, a coin flip. Probably the most...
Sequenom, Inc. Q1 2009 Earnings Call Transcript
Seeking Alpha
- 2009-04-30
Question-and-Answer SessionOperator Operator instructions. Harry Stylli Okay, operator. We are ready for the first question. Operator And your first question comes from Tony Butler with Barclays Capital. Tony Butler – Barclays Capital Thanks very much. Harry, three questions. One is what evidence do you have that the diagnostic test...
Glass Door
| Company | Employer Rating |
| Alcoa |  |
| CBS Corp |  |
| Johnson & Johnson | |
| Costco Wholesale |  |
|
IndustryTop Rated
